{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:21:32Z","timestamp":1793744492301,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    There is no FDA-approved drug for neurological disorders like spinocerebellar ataxia type 3. CAG repeats mutation in the ATXN3 gene, causing spinocerebellar ataxia type 3 disease. Symptoms include sleep cycle disturbance, neurophysiological abnormalities, autonomic dysfunctions, and depression. This research focuses on drug discovery against ATXN3 using phytochemicals of different plants. Three phytochemical compounds (flavonoids, diterpenoids, and alkaloids) were used as potential drug candidates and screened against the ATXN3 protein. The 3D structure of ATXN3 protein and phytochemicals were retrieved and validation of the protein was 98.1% Rama favored. The protein binding sites were identified for the interaction by CASTp. ADMET was utilized for the pre-clinical analysis, including solubility, permeability, drug likeliness and toxicity, and chamanetin passed all the ADMET properties to become a lead drug candidate. Boiled egg analysis attested that the ligand could cross the gastrointestinal tract. Pharmacophore analysis showed that chamanetin has many hydrogen acceptors and donors which can form interaction bonds with the receptor proteins. Chamanetin passed all the screening analyses, having good absorption, no violation of Lipinski\u2019s rule, nontoxic properties, and good pharmacophore properties. Chamanetin was one of the lead compounds with a \u2212\u20097.2\u00a0kcal\/mol binding affinity after screening the phytochemicals. The stimulation of ATXN3 showed stability after 20\u00a0ns of interaction in an overall 50\u00a0ns MD simulation. Chamanetin (Flavonoid) was predicted to be highly active against ATXN3 with good drug-like properties.\n                    <jats:italic>In-silico<\/jats:italic>\n                    active drug against ATXN3 from a plant source and good pharmacokinetics parameters would be excellent drug therapy for SC3, such as flavonoids (Chamanetin).\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-51954-3","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T11:13:13Z","timestamp":1705489993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["The natural breakthrough: phytochemicals as potent therapeutic agents against spinocerebellar ataxia type 3"],"prefix":"10.1038","volume":"14","author":[{"given":"Muhammad","family":"Naveed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouman","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimra","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnoor","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metab","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah F.","family":"Alasmari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thamer H.","family":"Albekairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"issue":"2","key":"51954_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/WCO.0b013e3282f7673d","volume":"21","author":"U R\u00fcb","year":"2008","unstructured":"R\u00fcb, U., Brunt, E. R. & Deller, T. New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado\u2013Joseph disease). Curr. Opin. Neurol. 21(2), 111\u2013116 (2008).","journal-title":"Curr. Opin. Neurol."},{"issue":"9","key":"51954_CR2","doi-asserted-by":"publisher","first-page":"e0204438","DOI":"10.1371\/journal.pone.0204438","volume":"13","author":"L Zeng","year":"2018","unstructured":"Zeng, L. et al. Loss of the spinocerebellar ataxia type 3 disease protein ATXN3 alters transcription of multiple signal transduction pathways. PLoS One 13(9), e0204438 (2018).","journal-title":"PLoS One"},{"issue":"2","key":"51954_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00415-018-9076-4","volume":"266","author":"R Sullivan","year":"2019","unstructured":"Sullivan, R. et al. Spinocerebellar ataxia: An update. J. Neurol. 266(2), 533\u2013544 (2019).","journal-title":"J. Neurol."},{"key":"51954_CR4","unstructured":"Mouse, H.A. and H. Atlas, Handbook of Proteolytic Enzymes, Volumes 1, 2 and 3 (2013)."},{"key":"51954_CR5","volume-title":"Genetic Instabilities and Neurological Diseases","author":"RD Wells","year":"2011","unstructured":"Wells, R. D. & Ashizawa, T. Genetic Instabilities and Neurological Diseases Vol. 31 (Elsevier, 2011)."},{"key":"51954_CR6","volume-title":"Progress in Molecular Biology and Translational Science","author":"DB Teplow","year":"2018","unstructured":"Teplow, D. B. Progress in Molecular Biology and Translational Science (Academic Press, 2018)."},{"issue":"2","key":"51954_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10048-016-0473-5","volume":"17","author":"KC Donis","year":"2016","unstructured":"Donis, K. C. et al. Spinocerebellar ataxia type 3\/Machado-Joseph disease starting before adolescence. Neurogenetics 17(2), 107\u2013113 (2016).","journal-title":"Neurogenetics"},{"key":"51954_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.omtm.2019.10.008","volume":"15","author":"R Martier","year":"2019","unstructured":"Martier, R. et al. Development of an AAV-based microRNA gene therapy to treat Machado-Joseph disease. Mol. Ther.-Methods Clin. Dev. 15, 343\u2013358 (2019).","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"51954_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.parkreldis.2016.03.005","volume":"26","author":"L-F Lei","year":"2016","unstructured":"Lei, L.-F. et al. Safety and efficacy of valproic acid treatment in SCA3\/MJD patients. Parkinsonism Relat. Disord. 26, 55\u201361 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"51954_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/pro.3730","volume":"29","author":"DS Goodsell","year":"2020","unstructured":"Goodsell, D. S. et al. RCSB protein data bank: Enabling biomedical research and drug discovery. Protein Science 29(1), 52\u201365 (2020).","journal-title":"Protein Science"},{"key":"51954_CR11","doi-asserted-by":"crossref","unstructured":"Laskowski, R. A., Furnham, N., & Thornton, J. M. The Ramachandran plot and protein structure validation. In Biomolecular Forms and Functions: A Celebration of 50 Years of the Ramachandran Map. 62\u201375 (World Scientific, 2013)","DOI":"10.1142\/9789814449144_0005"},{"key":"51954_CR12","doi-asserted-by":"crossref","unstructured":"Tian, W., et al., CASTp 3.0: computed atlas of surface topography of proteins. Nucleic acids research, 2018. 46(W1): p. W363-W367.","DOI":"10.1093\/nar\/gky473"},{"key":"51954_CR13","doi-asserted-by":"crossref","unstructured":"Naveed, M., et al., Assessment of Melia azedarach plant extracts activity against hypothetical protein of mycobacterium tuberculosis via GC-MS analysis and in-silico approaches. J. Comput. Biophys. Chem. (2023).","DOI":"10.1142\/S2737416523500631"},{"issue":"D1","key":"51954_CR14","doi-asserted-by":"publisher","first-page":"D1102","DOI":"10.1093\/nar\/gky1033","volume":"47","author":"S Kim","year":"2019","unstructured":"Kim, S. et al. PubChem 2019 update: Improved access to chemical data. Nucleic Acids Res. 47(D1), D1102\u2013D1109 (2019).","journal-title":"Nucleic Acids Res."},{"key":"51954_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","volume-title":"Chem. Biol.","author":"S Dallakyan","year":"2015","unstructured":"Dallakyan, S. & Olson, A. J. Small-molecule library screening by docking with PyRx. In Chem. Biol. 243\u2013250 (Springer, 2015)."},{"issue":"6","key":"51954_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1147\/JRD.2018.2883977","volume":"62","author":"DR Koes","year":"2018","unstructured":"Koes, D. R. The Pharmit backend: A computer systems approach to enabling interactive online drug discovery. IBM J. Res. Dev. 62(6), 1\u20133 (2018).","journal-title":"IBM J. Res. Dev."},{"issue":"4","key":"51954_CR17","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3390\/biomedicines11041041","volume":"11","author":"M Naveed","year":"2023","unstructured":"Naveed, M. et al. Artificial intelligence assisted pharmacophore design for philadelphia chromosome-positive leukemia with gamma-tocotrienol: A toxicity comparison approach with asciminib. Biomedicines 11(4), 1041 (2023).","journal-title":"Biomedicines"},{"issue":"1","key":"51954_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7(1), 1\u201313 (2017).","journal-title":"Sci. Rep."},{"key":"51954_CR19","unstructured":"Molinspiration, C., Calculation of molecular properties and bioactivity score. http:\/\/www.molinspiration.com\/cgi-bin\/properties (2011)."},{"issue":"W1","key":"51954_CR20","doi-asserted-by":"publisher","first-page":"W257","DOI":"10.1093\/nar\/gky318","volume":"46","author":"P Banerjee","year":"2018","unstructured":"Banerjee, P. et al. ProTox-II: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 46(W1), W257\u2013W263 (2018).","journal-title":"Nucleic Acids Res."},{"key":"51954_CR21","first-page":"92037","volume":"10550","author":"R Huey","year":"2012","unstructured":"Huey, R., Morris, G. M. & Forli, S. Using AutoDock 4 and AutoDock vina with AutoDockTools: A tutorial. Scripps Res. Inst. Mol. Graph. Lab. 10550, 92037 (2012).","journal-title":"Scripps Res. Inst. Mol. Graph. Lab."},{"issue":"1","key":"51954_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/vaccines11010131","volume":"11","author":"HM Rehman","year":"2023","unstructured":"Rehman, H. M. et al. Identification of NS2B-NS3 protease inhibitors for therapeutic application in ZIKV infection: A pharmacophore-based high-throughput virtual screening and MD simulations approaches. Vaccines 11(1), 131 (2023).","journal-title":"Vaccines"},{"key":"51954_CR23","volume-title":"LigPlot+: Multiple Ligand\u2013Protein Interaction Diagrams for Drug Discovery","author":"RA Laskowski","year":"2011","unstructured":"Laskowski, R. A. & Swindells, M. B. LigPlot+: Multiple Ligand\u2013Protein Interaction Diagrams for Drug Discovery (ACS Publications, 2011)."},{"issue":"2","key":"51954_CR24","doi-asserted-by":"publisher","first-page":"e1298","DOI":"10.1002\/wcms.1298","volume":"7","author":"S Yuan","year":"2017","unstructured":"Yuan, S., Chan, H. S. & Hu, Z. Using PyMOL as a platform for computational drug design. Wiley Interdiscip. Rev. Comput. Mol. Sci. 7(2), e1298 (2017).","journal-title":"Wiley Interdiscip. Rev. Comput. Mol. Sci."},{"key":"51954_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1","author":"MJ Abraham","year":"2015","unstructured":"Abraham, M. J. et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1, 19\u201325 (2015).","journal-title":"SoftwareX"},{"key":"51954_CR26","doi-asserted-by":"publisher","first-page":"138894","DOI":"10.1016\/j.cplett.2021.138894","volume":"780","author":"RS Tumskiy","year":"2021","unstructured":"Tumskiy, R. S. & Tumskaia, A. V. Multistep rational molecular design and combined docking for discovery of novel classes of inhibitors of SARS-CoV-2 main protease 3CLpro. Chem. Phys. Lett. 780, 138894 (2021).","journal-title":"Chem. Phys. Lett."},{"issue":"3","key":"51954_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.0009-9163.2004.00213.x","volume":"65","author":"Y Wu","year":"2004","unstructured":"Wu, Y. et al. Genetic testing in spinocerebellar ataxia in Taiwan: expansions of trinucleotide repeats in SCA8 and SCA17 are associated with typical Parkinson\u2019s disease. Clin. Genet. 65(3), 209\u2013214 (2004).","journal-title":"Clin. Genet."},{"issue":"1","key":"51954_CR28","first-page":"54","volume":"57","author":"P Maciel","year":"1995","unstructured":"Maciel, P. et al. Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am. J. Hum. Genet. 57(1), 54 (1995).","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"51954_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/jnc.14541","volume":"148","author":"CA Matos","year":"2019","unstructured":"Matos, C. A., de Almeida, L. P. & N\u00f3brega, C. Machado-Joseph disease\/spinocerebellar ataxia type 3: Lessons from disease pathogenesis and clues into therapy. J. Neurochem. 148(1), 8\u201328 (2019).","journal-title":"J. Neurochem."},{"issue":"9","key":"51954_CR30","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.3390\/ijms21093063","volume":"21","author":"Y-S Chen","year":"2020","unstructured":"Chen, Y.-S. et al. Identifying therapeutic targets for spinocerebellar ataxia type 3\/Machado\u2013Joseph disease through integration of pathological biomarkers and therapeutic strategies. Int. J. Mol. Sci. 21(9), 3063 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"51954_CR31","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3390\/biomedicines10020505","volume":"10","author":"Y-S Lin","year":"2022","unstructured":"Lin, Y.-S. et al. IGF-1 as a potential therapy for spinocerebellar ataxia type 3. Biomedicines 10(2), 505 (2022).","journal-title":"Biomedicines"},{"issue":"13","key":"51954_CR32","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2174\/1568026620666200416085330","volume":"20","author":"G Maan","year":"2020","unstructured":"Maan, G. et al. Role of flavonoids in neurodegenerative diseases: Limitations and future perspectives. Curr. Top. Med. Chem. 20(13), 1169\u20131194 (2020).","journal-title":"Curr. Top. Med. Chem."},{"issue":"15","key":"51954_CR33","first-page":"6972","volume":"27","author":"M Naveed","year":"2023","unstructured":"Naveed, M. et al. Halogens engineering-based design of agonists for boosting expression of frataxin protein in Friedreich\u2019s ataxia. Eur. Rev. Med. Pharm. Sci. 27(15), 6972\u20136984 (2023).","journal-title":"Eur. Rev. Med. Pharm. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51954-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51954-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51954-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T11:24:43Z","timestamp":1705490683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51954-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51954"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-51954-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,17]]},"assertion":[{"value":"7 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1529"}}